Gilead's Sunlenca Shows 100% Efficacy, Superior to Truvada in HIV Prevention Trial

Jun 20, 2024, 01:45 PM

Gilead Sciences announced that its experimental twice-yearly injectable drug, lenacapavir, also known as Sunlenca, demonstrated 100% efficacy in preventing HIV infections in a late-stage trial. The study, which included over 2,000 women and adolescent girls in Africa, showed that lenacapavir was superior to the company's existing daily pill, Truvada, for pre-exposure prophylaxis (PrEP). The trial, known as PURPOSE 1, is part of the most comprehensive and diverse HIV prevention trial program ever conducted. The positive results led to a significant increase in Gilead's stock price, which rose by over 8%. Researcher Joe Eron highlighted the remarkable outcome of having no infections in the trial participants. The success of this trial positions lenacapavir as a potentially powerful new regimen for HIV prevention. The study was reported by Jason Mast.